MONTREAL, QUEBEC -- (MARKET WIRE) -- March 13, 2007 -- Ambrilia Biopharma Inc. (TSX: AMB) and Mallinckrodt Pharmaceuticals' Brands business today announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a pivotal Phase 3 clinical trial in the United States for Ambrilia's proprietary, improved formulation of Octreotide.
